Form 4: Medtronic Executive Reports Tax-Related Share Disposition

EVP & President of Cardiovascular Harry Skip Kiil disposed of 6,817 Medtronic shares to cover tax obligations.

Summary

• Harry Skip Kiil, EVP & President of Cardiovascular at Medtronic, disposed of 6,817 ordinary shares.
• The transaction occurred on June 4, 2026, at a price of $83.32 per share.
• The disposition was executed to satisfy tax withholding requirements related to the vesting of performance-based restricted stock units on April 24, 2026.
• Following this transaction, the reporting person maintains a direct beneficial ownership of 41,416 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a mandatory tax settlement rather than a strategic divestment.

Positives

• The transaction was a routine tax withholding event rather than a discretionary market sale, indicating continued alignment with company equity.

Negatives

• Reduction in the total number of shares held directly by a key executive.

Risks

• None identified; this is a standard administrative transaction related to compensation vesting.

Future Outlook

Not applicable as this is a retrospective disclosure of a completed transaction.

Industry Context

StockSavvy.ai notes that routine tax-related share dispositions by senior executives are standard practice in the medical device industry and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices at large-cap medical technology firms like Abbott Laboratories and Boston Scientific.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax withholding.

Next Steps

• None

Key Dates

Keywords

Medtronic, MDT, Insider Trading, Form 4, Executive Compensation, Cardiovascular